Global High Content Screening Instruments Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global High Content Screening Instruments Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

High-Content Screening (HCS), also known as High-Content Analysis (HCA), is an approach to cell biology that combines automated imaging and quantitative data analysis in a high-throughput format suitable for large-scale applications such as drug discovery and systems biology. High Content Screening Instruments are advanced imaging technology for high-throughput screening (HTS) used in analyzing and extracting quantitative multi-parametric data in cellular studies.

Market Overview:

The latest research study on the global High Content Screening Instruments market finds that the global High Content Screening Instruments market reached a value of USD 436.73 million in 2023. It’s expected that the market will achieve USD 641.41 million by 2029, exhibiting a CAGR of 6.62% during the forecast period.

Increase in neurodegenerative diseases such as cancer and Alzheimer’s disease

Increasing cases of neurodegenerative life-threatening diseases such as cancer, spinal muscular atrophy, Alzheimer, and Parkinson's across the globe are expected to drive demand for advanced healthcare services. This has led international players across the globe to invest considerably in research and development to launch innovative products and to cater to the demand across the supply chain shortly. For instance, according to the World Health Organization (WHO) globally the number of deaths from cancer will continue to rise and reach around 13.1 billion by 2031. It also suggests that the global prevalence of cancer will increase by around 75% from 2008 to 2031. The increasing growth of cancer all over the globe will lead to an increased number of patients who will undergo cancer management and treatment. This in turn would increase the demand for more novel biologics thereby driving the growth of the high content screening instruments market.

Region Overview:

In 2022, the share of the High Content Screening Instruments market in North America stood at 37.83%.

Company Overview:

PerkinElmer is one of the major players operating in the High Content Screening Instruments market, holding a share of 19.99% in 2023.

Segmentation Overview:

Among different product types, Primary Screening and Secondary Screening segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Pharmaceutical and Biotechnology Companies segment occupied the biggest share from 2018 to 2022.

Key Companies in the global High Content Screening Instruments market covered in Chapter 3:

Thermo Fisher
Miltenyi Biotec
Logos Biosystems
Danaher
TissueGnostics
PerkinElmer
Yokogawa
Nikon

In Chapter 4 and Chapter 14.2, on the basis of types, the High Content Screening Instruments market from 2019 to 2030 is primarily split into:

Target Identification and Validation
Primary Screening and Secondary Screening
Toxicity Studies
Compound Profiling
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the High Content Screening Instruments market from 2019 to 2030 covers:

Pharmaceutical and Biotechnology Companies
Academic and Government Institutes
Contract Research Organizations (CROs)
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)